What Deplat Treats: Main Uses and Benefits

Deplat is a prescription medication generally used to manage the risk of serious atherothrombotic events, which are problems caused by blood clots and hardening of the arteries. It is used for patients with a history of recent myocardial infarction (heart attack), recent stroke, or established peripheral arterial disease.

The medication is also commonly applied in the context of Acute Coronary Syndrome (ACS), and its therapeutic benefit may assist in managing the risk of a subsequent event. Its use is considered relevant for managing conditions where symptoms may intensify temporarily, which contributes to easing the overall symptom load. It helps address the symptom cluster of increased physiological stress and supports general well-being during symptomatic phases.

Deplat is also considered relevant when supportive assistance is needed following certain coronary revascularization procedures, such as the placement of a coronary stent. This use may assist with maintaining functional stability and supports the patient's recovery following the intervention.

---

Supportive Information: Symptom Management

The medication is commonly used to manage the risk factors associated with symptoms related to physical discomfort.

The eligibility profile for Deplat (Clopidogrel) is strictly defined by regulatory authorities for use in adult patients. The medicine is contraindicated and must not be used by individuals experiencing active pathological bleeding, such as an intracranial hemorrhage or peptic ulcer, or by those with a known hypersensitivity to clopidogrel. Use is also prohibited in patients with severe hepatic impairment [1.5].

Restrictions and Limited Eligibility

• Pediatric Use: Safety and efficacy have not been established in the pediatric population, and its use in children is generally not recommended [1.3].
• Metabolic Status: Patients identified as CYP2C19 poor metabolizers may have diminished antiplatelet activity, and official labeling suggests considering an alternative P2Y12 inhibitor [1.7].
• Organ Function: Caution is advised in patients with renal impairment or moderate hepatic disease due to limited therapeutic experience in these groups [1.5].
• Pregnancy/Lactation: Use during pregnancy and lactation is not recommended [1.2, 1.3].

Deplat (clopidogrel) can interact with several other medicines, which may affect how Deplat works or increase the risk of bleeding. It is essential to inform your doctor or pharmacist of all prescription and non-prescription drugs, herbal remedies, and supplements you are taking.

Increased Risk of Bleeding

Concomitant use with other medications that affect blood clotting can significantly increase the risk and intensity of bleeding. Caution and close monitoring are necessary when Deplat is taken with:

• Other Antiplatelet Agents: Such as aspirin (acetylsalicylic acid), ticagrelor, or prasugrel.
• Anticoagulants (Blood Thinners): Such as warfarin, heparin, rivaroxaban, apixaban, or dabigatran.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Such as ibuprofen and naproxen, which can also increase the risk of gastrointestinal bleeding.
• Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Certain antidepressants, like fluoxetine or sertraline.

---

Reduced Effectiveness of Deplat

Deplat is a prodrug that requires activation by the CYP2C19 enzyme in the liver. Medicines that inhibit this enzyme can lower the level of the active form of clopidogrel, making Deplat less effective. Concomitant use with strong or moderate CYP2C19 inhibitors is generally discouraged:

• Proton Pump Inhibitors (PPIs): Specifically omeprazole and esomeprazole. Alternative acid-reducing agents may be prescribed if needed.
• Other CYP2C19 Inhibitors: Including some antifungals (e.g., fluconazole, voriconazole) and certain HIV medicines.

---

Other Interactions

• Opioids: Certain opioid pain medications may reduce the absorption of clopidogrel, potentially decreasing its effectiveness.
• Grapefruit Juice: May reduce the effectiveness of clopidogrel by interfering with its metabolism. Avoid consuming grapefruit or its juice during treatment.

Always discuss all current and planned medications with your healthcare provider to manage potential interactions safely.

Bioactivation and Irreversible P2Y12 Blockade

The drug's mechanism requires an essential initial step: the inactive parent compound is metabolized by Cytochrome P450 (CYP) enzymes, primarily CYP2C19, into its Active Thiol Metabolite. This metabolite then permanently binds to the P2Y12 receptor on the platelet surface, acting as an irreversible antagonist. This crucial bioactivation step and subsequent blockade are the foundation of the drug's activity, modulating activity within the P2Y12 receptor system.

---

Halting the Platelet Aggregation Cascade

The irreversible P2Y12 antagonism effectively halts the internal signaling cascade normally initiated by Adenosine Diphosphate (ADP). By blocking this upstream signal, the drug prevents the necessary activation of the Glycoprotein IIb/IIIa receptor complex, which serves as the final molecular bridge for platelet cross-linking. This modification of early molecular steps results in the suppression of platelet aggregation, suppressing P2Y12 receptor signaling. Due to the covalent bond, this anti-aggregatory effect persists for the entire lifespan of the affected platelet.

How Deplat (Clopidogrel) Is Used: Administration Guidelines

Deplat, which contains clopidogrel, is an oral medication with a structured administration protocol. The proper usage follows specific dosing patterns and schedules that depend on the condition being addressed, always administered as a film-coated tablet.

Dosing and Administration

The standard approach involves a maintenance dose of 75 mg taken once daily for long-term use, though treatment often begins with a higher loading dose to rapidly establish the intended effect. These patterns are defined by the specific condition being managed.

Condition / Regimen	Administration Pattern
Established Atherothrombotic Disease (e.g., Recent Stroke, Peripheral Arterial Disease)	75 mg once daily without a loading dose.
Acute Coronary Syndrome (ACS)	Initial single 300 mg oral loading dose, followed by 75 mg once daily.

---

Administration Conditions and Frequency

Deplat is consistently taken once daily. The tablet can be administered with or without food. For most uses in ACS, the medication is administered in conjunction with aspirin.

Missed Dose Guidance: If a dose is missed by less than 12 hours, it should be taken immediately, and the regular schedule should be resumed. If missed by more than 12 hours, the dose should be skipped, and the patient should simply return to the next regularly scheduled dose.

Research evidence / Overview of Studies for Deplat (Clopidogrel)

---

Evidence for Use in Secondary Prevention of Atherothrombotic Events

Deplat was studied for patients who have already experienced a heart attack (recent myocardial infarction), an ischemic stroke, or who have established peripheral arterial disease (PAD). Large-scale, long-term Randomized Controlled Trials (RCTs) were evaluated in research that sometimes included comparisons with other antiplatelet agents. These studies monitored patient outcomes over follow-up durations extending from two to three years. The primary outcomes examined were the frequency of major events, specifically a composite endpoint of non-fatal myocardial infarction, non-fatal ischemic stroke, or vascular mortality.

Studies reported measurements of the frequency of combined cardiovascular events across the diverse groups included in the research. Research is ongoing to explore how differences in a patient’s unique metabolic profile may influence the antiplatelet response observed in some studies.

---

Evidence for Use Following Coronary Artery Procedures (Post-Revascularization)

Deplat was evaluated in research exploring its use following procedures such as the placement of a coronary stent. Dedicated RCTs have been conducted to examine the use of Dual Antiplatelet Therapy (DAPT), which combines clopidogrel with aspirin. These studies monitored adult populations who underwent percutaneous coronary intervention (PCI). The primary outcomes studied included device-related events, such as the occurrence of stent thrombosis and the need for Target Lesion Revascularization (TLR).

Data show patterns related to the rates of stent thrombosis and major cardiovascular events in patients observed in these studies. It is not yet clear whether a single optimal duration of DAPT exists for all patients. Research is ongoing to further explore the role of clopidogrel DAPT in various patient groups.

---

Assessing Long-Term Studies and Durability of Effect

Long-term follow-up was observed in some studies, with major trials having observed responses over defined time intervals extending to two to three years. These long-term studies contribute to the broader evidence landscape regarding the duration of the observed antiplatelet action.

However, long-term effects are not fully established beyond these follow-up periods. There is limited information for outcomes beyond five years, and the durability of the antiplatelet effect after stopping treatment is an area where data are still emerging.

Key Studies & References CLOPIDOGREL BISULFATE tablet, film coated (DailyMed - NIH)

Storage and Disposal of Deplat

Deplat (Clopidogrel) tablets must be stored at Controlled Room Temperature, typically maintained between 20 C and 25 C (68 F and 77 F), with permitted short excursions up to 30 C. The medication must be protected from moisture and light and should be kept in its original container to maintain stability. For products supplied in multi-dose bottles, an official in-use limit of 6 months after first opening may apply.

Handling and Safety

Per official labeling, the product must be stored in a location inaccessible to children, as it must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Deplat should be discarded following official guidelines, preferably through a community drug take-back program. If a take-back program is unavailable, the product should not be flushed down the toilet. Instead, it must be mixed with an undesirable material, such as dirt or used coffee grounds, placed in a sealed container, and then thrown into the household trash.